Evidence map›Paper›PMID 32377929›Full record

ReviewPharmaceutical research2020

L-Type amino acid transporter 1 as a target for drug delivery.

Elena Puris, Mikko Gynther, Seppo Auriola, Kristiina M Huttunen

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Elena PurisSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. elena.puris@uni-heidelberg.de.ORCID http://orcid.org/0000-0002-1769-389X
Mikko GyntherSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.
Seppo AuriolaSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.
Kristiina M HuttunenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.
University of Eastern Finland · FI

Funding

Academy of Finland 294227, 307057
6 · The paper itself

Abstract

Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers. The transporter is predominantly expressed in cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow and several types of cancer. Its physiological function is to mediate Na

Indexed as

AnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrainCentral Nervous SystemDrug CarriersDrug Delivery SystemsHumansLarge Neutral Amino Acid-Transporter 1Positron-Emission TomographyAntineoplastic AgentsDrug CarriersLarge Neutral Amino Acid-Transporter 1drug delivery systemsL-type amino acid transporter 1membrane transportertargeting

Identifiers

PMID32377929
PMCPMC7203094
OpenAlexW3023498751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.